Global Advanced Therapy Medicinal Products CDMO Market

Report ID : 1369 | Published : 2022-10-06 | Pages: 170 | Format: PDF/EXCEL

The market size of the Global Advanced Therapy Medicinal Products CDMO market in the year 2021 is valued at 6.37 billion and is predicted to reach 16.15 billion by the year 2030 at an 11.25% CAGR during the forecast period.

Advanced therapy medicinal products are a class of human-use biological products that include gene therapy, cell therapy, and tissue-engineered products. The expanding clinical studies of ATMP and rising awareness and belief among researchers about the benefits of advanced treatment are associated with the market's expansion. The rising demand for sophisticated therapies is driving market expansion. The growth is attributable to the increasing occurrence of rare and life-threatening disorders, such as metabolic and ocular diseases, and increased investment in R&D of advanced therapeutic medical goods. Furthermore, ATMPs such as mesenchymal stem cells (MSCs) represent a novel treatment for the COVID-19 virus. Due to the complexity of the manufacturing process, the COVID-19 pandemic has dramatically affected the cell and gene therapy sector. Tissue engineering has significantly benefited from technological advances in recent years. This approach aids in the replacement or restoration of injured tissues and organ function.

Similarly, gene and cell therapy are attracting many patients to treat rare disorders, the prevalence of which is increasing globally. Numerous prominent players use market strategies such as technical alliances and collaborations, mergers and acquisitions, unique product debuts with approvals, R & D activities, strategic initiatives, training services, and regional expansion to build a stronghold in the market growth.

Market Segmentation:

The Advanced Therapy Medicinal Products CDMO market is segmented on the product, phase, and indication. Based on product, the market is segmented into gene therapy, cell therapy, tissue-engineered and others (combined ATMPs, for example, biodegradable matric or scaffold). Based on phase, the Advanced Therapy Medicinal Products CDMO are segmented into phases I, II, III, and IV. Based on the indication, the Advanced Therapy Medicinal Products CDMO are segmented into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology and others.

Based on product, the gene therapy segment is accounted as a significant contributor to the Advanced Therapy Medicinal Products CDMO market.

Based on product, the market is segmented into gene therapy, cell therapy, tissue-engineered and others (combined ATMPs, for example, biodegradable matric or scaffold). The gene therapy segment is expected to account for the highest share of the market. The rapid expansion of the segment can be ascribed to therapeutic breakthroughs since the treatment can alter and improve genetics or modify the targeted treatment. Another aspect driving expansion is increased awareness, which leads to patients wanting this therapy even during the clinical stages. Gene therapy has seen rapid expansion in recent years because of its effectiveness in penetrating cells and beginning genetic materials.

The oncology segment witnessed growth at a rapid rate.

Based on the indication, the Advanced Therapy Medicinal Products CDMO are segmented into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology and others. The oncology segment dominated the market. The increasing incidence of cancer and chronic diseases due to the growing elderly population is contributed to the segment's growth. Oncology is a medical speciality that diagnoses and treats cancer. ATMPs were first used to find a breakthrough in cancer treatment, and as a result, this segment has seen the most expertise and effort over the years.

The North American Advanced Therapy Medicinal Products CDMO market holds a significant regional revenue share.

The North American Advanced Therapy Medicinal Products CDMO market is expected to register the highest market share in revenue shortly. The region is expected to account for the significant share of market revenue. North America's market relevance is achievable due to rising awareness of advanced therapy and expanding outsourcing operations. In addition, the United States has been a pioneer in R&D operations to provide new treatments to the healthcare business. As a result of these factors, the market is expected to grow at a rapid pace in the approaching years. In addition, Asia Pacific is projected to expand rapidly in the global Advanced Therapy Medicinal Products CDMO market because of developments in treatment technology and increased outsourcing activity in the region. The leading competitors in the advanced therapy medicinal products CDMO market are working hard to meet the region's need for advanced therapy therapeutic goods.

Competitive Landscape

The key players in the Advanced Therapy Medicinal Products CDMO market have shifted their focus toward product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance their product portfolio and strengthen their global market footprint. Some major key players in the Advanced Therapy Medicinal Products CDMO market are Celonic; Bio Elpida; CGT Catapult; Rentschler Biopharma SE; AGC Biologics; Catalent; Lonza; WuXi Advanced Therapies; BlueReg; Minaris Regenerative Medicine; Patheon.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Advanced Therapy Medicinal Products CDMO Market Snapshot

Chapter 4. Global Advanced Therapy Medicinal Products CDMO Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis

5.1. by Product Type & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Product Type:

5.2.1. Gene Therapy

5.2.2. Cell Therapy

5.2.3. Tissue Engineered

5.2.4. Others (Combined ATMPs, for example, biodegradable matric or scaffold)

Chapter 6. Market Segmentation 2: by Phase Estimates & Trend Analysis

6.1. by Phase & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Phase:

6.2.1. Phase I

6.2.2. Phase II

6.2.3. Phase III

6.2.4. Phase IV

Chapter 7. Market Segmentation 3: by Indication Estimates & Trend Analysis

7.1. by Indication & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Indication:

7.2.1. Oncology

7.2.2. Cardiology

7.2.3. Central Nervous System

7.2.4. Musculoskeletal

7.2.5. Infectious Disease

7.2.6. Dermatology

7.2.7. Endocrine, Metabolic, Genetic

7.2.8. Immunology & Inflammation

7.2.9. Ophthalmology

7.2.10. Hematology

7.2.11. Gastroenterology

7.2.12. Others

Chapter 8. Advanced Therapy Medicinal Products CDMO Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Advanced Therapy Medicinal Products CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2022-2030

8.1.2. North America Advanced Therapy Medicinal Products CDMO Market Revenue (US$ Million) Estimates and Forecasts by Phase, 2022-2030

8.1.3. North America Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Indication, 2022-2030

8.1.4. North America Advanced Therapy Medicinal Products CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.2. Europe

8.2.1. Europe Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Product Type, 2022-2030

8.2.2. Europe Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Phase, 2022-2030

8.2.3. Europe Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Indication, 2022-2030

8.2.4. Europe Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by country, 2022-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Product Type, 2022-2030

8.3.2. Asia Pacific Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Phase, 2022-2030

8.3.3. Asia-Pacific Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Indication, 2022-2030

8.3.4. Asia Pacific Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by country, 2022-2030

8.4. Latin America

8.4.1. Latin America Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Product Type, 2022-2030

8.4.2. Latin America Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Phase, 2022-2030

8.4.3. Latin America Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Indication, 2022-2030

8.4.4. Latin America Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by country, 2022-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Product Type, 2022-2030

8.5.2. Middle East & Africa Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Phase, 2022-2030

8.5.3. Middle East & Africa Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by Indication, 2022-2030

8.5.4. Middle East & Africa Advanced Therapy Medicinal Products CDMO Market revenue (US$ Million) by country, 2022-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Celonic

9.2.2. Bio Elpida

9.2.3. CGT Catapult

9.2.4. Rentschler Biopharma SE

9.2.5. AGC Biologics

9.2.6. Catalent

9.2.7. Lonza

9.2.8. WuXi Advanced Therapies

9.2.9. BlueReg

9.2.10. Minaris Regenerative Medicine

9.2.11. Patheon

9.2.12. Other Prominent Players

By Product-

  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered
  • Others (Combined ATMPs, for example, biodegradable matric or scaffold)

By Phase-

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Indication-

  • Oncology
  • Cardiology
  • Central Nervous System
  • Musculoskeletal
  • Infectious Disease
  • Dermatology
  • Endocrine, Metabolic, Genetic
  • Immunology & Inflammation
  • Ophthalmology
  • Hematology
  • Gastroenterology
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients